Journal
JOURNAL OF PROTEOME RESEARCH
Volume 10, Issue 3, Pages 1383-1395Publisher
AMER CHEMICAL SOC
DOI: 10.1021/pr101154j
Keywords
serum amyloid A; lung cancer; serum; biomarkers; metastasis
Categories
Funding
- Korean Ministry of Education, Science and Technology (MEST) [FPR08A2-120]
- Small and Medium Business Administration (SMBA) [S0806222C034740010010021]
- Ministry of Knowledge Economy (MKE) [RT104-01-01, 70003433-2008-01]
Ask authors/readers for more resources
Lung cancer is recently regarded as an overhealed inflammatory disease. Serum amyloid A (SAA) is known as an acute phase protein, but it is likely involved in the cancer pathogenesis. We identified both SAA1 and SAA2 in the pooled sera of lung cancer patients but not in the healthy control, by LC-MS/MS analysis. We found that about 14-fold higher levels of SAA in lung cancer patients' sera and plasma compared to healthy controls by ELISA using total 350 samples (13.89 +/- 37.18 vs 190.49 +/- 234.70 ug/mL). The SAA levels were also significantly higher than in other pulmonary disease or other cancers. An immunohistochemical study using tissue microarray showed that, unlike other cancer tissues, lung cancer tissues highly express SAA. Further in vitro experiments showed that SAA is induced from lung cancer cells by the interaction with THP-1 monocytes and this, in return, induces MMP-9 from THP-1. In in vivo animal models, overexpressed SAA promoted Lewis lung carcinoma,(LLC) cells to metastasize and colonize in the lung. Our data suggest that a higher concentration of SAA Can serve as an indicator of. lung adenocarcinoma and represents a therapeutic target for the inhibition of lung cancer metastasis.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available